BioHealth Innovation Inc., of Rockville, an organization focused on commercializing bio-health innovations and increasing access to early-stage funding in Maryland, announced on Monday an agreement with Roche Pharma Research and Early Development to advance health care technologies coming Central Maryland. BHI will identify technologies from academic institutions, federal laboratories and startups that Roche will evaluate for potential development opportunities. Roche is a Switzerland-headquarted pharmaceutical company. BHI and Roche will look primarily for opportunities in oncology, neuroscience, ophthalmology, rare diseases, immunological and infectious diseases. Financial terms for the agreement were not disclosed. As part of the agreement, Judith Dunn, Roche Pharma Research and Early Development’s global head of clinical development and head of Roche Innovation Center in New York, has been unanimously approved by the BHI board of directors to serve as the Roche representative to the BHI board.